Clinical Trial

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Study acronym: STOP-HS LTE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Protocol Amendment History 72 amendments
This ClinicalTrials.gov record has been amended 72 times since 2024-01-09; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2026-02-05
Status change: Not Yet Recruiting → Recruiting 2024-02-07
Trial Details
NCT Number NCT06212999
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa (HS)
Enrollment 617 participants
Start Date 2024-01-30
Primary Completion 2026-12-26 (estimated)
Study Completion 2026-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-23